Pacira | PCRX - Gross Profit On Sales

Stock Price
21.91
Daily Change
-0.68 -3.01%
Monthly
7.51%
Yearly
-8.90%
Q1 Forecast
22.50

Pacira reported $142.25M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Assertio Holdings USD 22.24M 970K Jun/2024
Astellas Pharma JPY 456.81B 38.02B Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 16.6B 118M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025
Xoma 992K 846K Jun/2024
Zoetis USD 1.64B 73M Dec/2025